Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

CONCLUSION: These data suggest that for patients for whom weekly treatment with cetuximab presents a substantial burden to their quality of life, q2w dosing of cetuximab is a viable treatment option with a benefit:risk profile similar to that of the weekly regimen. PMID: 23745159 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research